We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.00
Bid: 47.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.255%)
Open: 48.00
High: 48.00
Low: 48.00
Prev. Close: 48.00
MIG3 Live PriceLast checked at -
Maven Income and Growth VCT 3 is an Investment Trust

To achieve long-term capital appreciation and generate income for Shareholders by investing in a diversified portfolio of securities in smaller, unquoted UK companies and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

21 Jul 2023 12:52

RNS Number : 8412G
Maven Income and Growth VCT 3 PLC
21 July 2023
 

Maven Income and Growth VCT 3 PLC

 

Interim Results for the Six Months Ended 31 May 2023

 

Highlights

 

· NAV total return at 31 May 2023 of 150.69p per share

 

· NAV at 31 May 2023 of 53.62p per share, after payment of the 2022 final dividend of 1.90p per share on 26 April 2023

 

· Interim dividend of 0.50p per share declared for payment on 25 August 2023

 

· Offer for Subscription closed, raising £6.75 million, with a further fund raising to be launched in Autumn 2023

 

· Two new private companies added to the portfolio

 

Overview

 

During the first half of the financial year, the macroeconomic environment remained challenging and growth prospects continue to be suppressed by ongoing inflationary pressures and rising interest rates. Against this backdrop, it is encouraging to report on the further progress that has been achieved by your Company. Whilst NAV total return has reduced modestly, compared to the position at the previous year end, most companies in the unlisted portfolio have continued to deliver revenue growth and achieve their commercial milestones. Notably, some of the most resilient performances have been from companies in the early stage portfolio, which helps to demonstrate the strength of the investment strategy that your Company has been following for a number of years. The Board and the Manager recognise the importance to Shareholders of regular tax free distributions and the Directors were pleased to declare an interim dividend of 0.50p per share for payment in August 2023.

 

Whilst the outlook for the UK economy has slightly improved, inflation remains stubbornly high and interest rates continue to rise, meaning that the prevailing economic conditions remain challenging for many businesses and consumers. Notwithstanding the market conditions, your Company has delivered a robust performance and it is worthwhile noting that across the portfolio the level of external debt and direct exposure to consumer facing sectors is low. The Board and the Manager believe that the underlying growth prospects for the majority of companies within the portfolio remain positive and that your Company is well positioned to make further progress in line with its long term investment objective.

 

Your Company continues to follow a strategy focused on constructing a large and sectorally diversified portfolio of dynamic and entrepreneurial private and AIM quoted companies that operate in defensive markets such as cyber security, data analytics, healthcare and Software-as-a-Service (SaaS), where growth is less dependent on the conditions in the wider economy. Most companies within the unlisted portfolio have continued to make positive progress, with some of the more mature holdings now trading ahead of pre-pandemic levels. In the earlier stage portfolio, the majority of companies are meeting their commercial milestones, increasing annual recurring revenue (ARR) and achieving further scale. In certain cases, where there has been a sustained positive performance, valuations have been uplifted. However, the valuation impact of improved revenues has been curtailed by the well-publicised reduction in valuation multiples across public and private markets, particularly within the technology sector.

 

In May 2023, your Company closed its most recent Offer for Subscription, raising a total of £6.75 million across the 2022/23 and 2023/24 tax years. This new capital provides additional liquidity to support the further expansion and development of the portfolio through the completion of new investments and the provision of follow-on funding to support those companies that are achieving commercial targets and require additional capital to fully scale before progressing to an exit. During the period, two new private companies were added to the portfolio, both of which provide disruptive software solutions and operate in attractive growth markets. Maven will generally only invest in companies that can demonstrate meaningful commercial traction and have the potential for further strong revenue growth. This is often measured in terms of contracted ARR, which provides a degree of visibility on the growth trajectory for each company. Maven's regional network of investment executives continues to review a healthy pipeline of opportunities across a wide range of sectors and, at the time of writing, there are a number of potential investments at various stages of due diligence and legal contract. Based on this pipeline, it is anticipated that there will be a good rate of new investment during the second half of the financial year.

 

Within the AIM quoted portfolio, performance has continued to be soft and, despite the generally encouraging underlying performance by most investee companies, certain share prices have declined further. Although some listed markets have experienced a recovery, investor sentiment towards AIM continues to be subdued and there has been very limited IPO and new share issuance activity to help stimulate demand. As a result of these market conditions, the value of your Company's AIM quoted portfolio has reduced. For the majority of holdings, the share price weakness reflects the general market volatility that has persisted throughout the period and the reduced investor appetite for smaller, earlier stage growth businesses. The Board and the Manager nevertheless believe that selective exposure to AIM offers scope to broaden the portfolio, as well as providing the ability to generate early liquidity if companies perform well. The Manager will, however, remain cautious towards any new AIM investments until there is clear evidence of a recovery, and an improvement in the quality and quantity of companies seeking VCT funding.

 

The Manager maintains an active approach to portfolio management, with a view to supporting investee companies throughout the period of ownership. The Maven appointed board representative works closely with each unlisted portfolio company that is considering, or is engaged in, a sale process, helping to identify the most suitable corporate finance advisor and potential acquirers that may be willing to pay a premium or strategic price for the business. Whilst there have been no material realisations during the period, there remains a good level of external interest in a number of portfolio companies and, based on historic trends, the Manager is optimistic that M&A activity will resume when economic conditions stabilise.

 

Liquidity Management

 

As Shareholders will be aware from recent Annual and Interim Reports, your Company maintains a proactive approach to liquidity management, with the objective of generating income from cash resources held prior to investment in VCT qualifying companies. This strategy also helps to satisfy the criteria of the Nature of Income condition, which is a mandatory requirement of the VCT legislation where not less than 70% of a VCT's income must be derived from shares or securities. To meet this requirement, the Board had previously approved the construction of a focused portfolio of permitted, non-qualifying holdings in carefully selected investment trusts with strong fundamentals and attractive income characteristics. The recent upward trend in interest rates has, however, required the Board and the Manager to revise the approach to funds held prior to investment. Following a whole of market review, the Manager has selected a number of leading money market funds and a portfolio of investment trusts that will allow your Company to maximise the income receivable on residual cash held prior to investment, whilst also ensuring compliance with the Nature of Income condition. During the reporting period, several new investments were completed in support of the revised liquidity management strategy, and details can be found in the Investments table in the Interim Report.

 

Interim Dividend

 

In respect of the year ending 30 November 2023, an interim dividend of 0.50p per share will be paid on 25 August 2023 to Shareholders who are on the register at 28 July 2023. Since the Company's launch, and after receipt of this interim dividend, a total of 97.57p per share will have been paid in tax free Shareholder distributions. It should be noted that payment of a dividend reduces the NAV of the Company by the total cost of the distribution.

 

Dividend Policy

 

Decisions on distributions take into consideration a number of factors, including the realisation of capital gains, the adequacy of distributable reserves, the availability of surplus revenue and the VCT qualifying level, all of which are kept under close and regular review.

 

The Board and the Manager recognise the importance of tax free distributions to Shareholders and, subject to the considerations outlined above, will seek, as a guide, to pay an annual dividend that represents 5% of the NAV per share at the immediately preceding year end.

 

As the portfolio continues to expand, and a greater proportion of holdings are in younger companies with growth potential, the timing of distributions will be more closely linked to realisation activity, whilst also reflecting the Company's requirement to maintain its VCT qualifying level. If larger distributions are required as a consequence of significant exits, this will result in a corresponding reduction in NAV per share. However, the Board and the Manager consider this to be a tax efficient means of returning value to Shareholders, whilst ensuring ongoing compliance with the VCT legislation.

 

Dividend Investment Scheme

 

Your Company operates a DIS, through which Shareholders can, at any time, elect to have their future dividend payments utilised to subscribe for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax relief applicable for the tax year in which they are allotted, subject to an individual Shareholder's particular circumstances.

 

In order for the DIS to apply to the interim dividend that is due to be paid on 25 August 2023, a mandate form must be received by the Registrar (The City Partnership) before 11 August 2023, this being the relevant dividend election date, and that election will apply to all future dividends until the Registrar is instructed to the contrary. The mandate form, terms & conditions and full details of the scheme (including tax considerations) are available from the Company's webpage at: mavencp.com/migvct3. Election to participate in the DIS can also be made through the Registrar's online investor hub at: maven-cp.cityhub.uk.com/login.

 

If a Shareholder is in any doubt about the merits of participating in the DIS, or their own tax status, they should seek advice from a suitably qualified adviser.

 

Offers for Subscription

 

On 7 October 2022, your Company, alongside Maven Income and Growth VCT PLC, Maven Income and Growth VCT 4 PLC and Maven Income and Growth VCT 5 PLC, launched Offers for Subscription for up to £30 million in aggregate, with over-allotment facilities for up to £10 million in aggregate. On 26 May 2023, the Offers closed with your Company having raised a total of £6.75 million across the 2022/23 and 2023/24 tax years.

 

With respect to the 2022/23 tax year, an allotment of 6,389,151 new Ordinary Shares completed on 8 February 2023, with a further allotment of 982,796 new Ordinary Shares on 3 March 2023 and a final allotment of 2,870,790 new Ordinary Shares on 5 April 2023. An allotment of 1,441,593 new Ordinary Shares for the 2023/24 tax year took place on 2 June 2023.

 

The Directors are confident that Maven's regional office network will continue to source and complete attractive investments in VCT qualifying companies across a range of sectors, and the additional liquidity provided by the fundraising will facilitate further expansion and development of the portfolio in line with the investment strategy. Furthermore, the funds raised will allow your Company to maintain its share buy-back policy, whilst also spreading costs over a wider asset base in line with the objective of maintaining a competitive total expense ratio for the benefit of all Shareholders.

 

Further to the announcement of 6 July 2023, the Directors have elected to launch a new Offer in Autumn 2023, which will run alongside Offers by the other Maven managed VCTs. Full details of the Offers will be included in the Prospectus, which is expected to be published in Autumn 2023.

 

Portfolio Developments

 

Integrated drug discovery services provider BioAscent Discovery continues to make strong progress and has consistently achieved double digit annual revenue growth in each of the four years since your Company first invested. To maintain this momentum, BioAscent is focused on expanding its range of services and the near term objective is to move into complementary areas such as custom protein production, immune-oncology and further translational assays. As part of the long term growth strategy, and to ensure that the business is able to meet the requirements of its global customer base, BioAscent is in advanced discussions to achieve a significant increase in laboratory and office space, whilst remaining at a single location in Scotland. This additional space will enable the company to increase its market presence by making the drug discovery process more efficient, which should help it to attract more clients and achieve further scale.

 

Graduate recruitment specialist Bright Network continues to make positive progress, with revenues now in excess of £11 million and over 900,000 active members. Its digital solution enables leading employers to identify, reach and recruit high quality graduates and young professionals and has established a leading market position. Working with over 300 partner firms such as Amazon, Bloomberg, Google and Vodafone, it offers a comprehensive range of services, including advice and support to assist its members in securing their first job or internship, as well as providing access to a range of in-person networking events. The business is committed to serving a diverse range of applicants and it is encouraging to note that 79% of the membership base are state educated, 55% are female and 40% are from first generation university households. During 2021, the business launched its Technology Academy, which seeks to address the digital skills shortage by providing high performing graduates with an intensive software development training programme, and then deploying them in client organisations. The Technology Academy has gained good commercial traction and already has consultants deployed with Lloyds Bank and Marks and Spencer. It was also named the Learning Solution of the Year at the 2022 Tiara Talent Tech Star Awards, which recognise excellence in the recruitment and talent acquisition industry.

 

Following a challenging period during the pandemic, when global electronic component shortages and supply chain disruption impacted order fulfilment capabilities, specialist manufacturer CB Technology has experienced a good recovery, with sales now back to pre-pandemic levels. Over recent years, the strategy to diversify the customer base away from a reliance on the oil & gas sector has been successful, with new clients secured in sectors such as communication, instrumentation and medical technology, where demand has remained resilient. To support future growth, the business continues to make strategic investments to ensure that it has the necessary infrastructure in place to best serve its clients. As part of this initiative, it is currently implementing a new enterprise resource planning (ERP) system, which will help to improve operational efficiencies. With a strong orderbook, the prospects for the year ahead are positive.

 

Over recent years, cybercrime has become an increasing threat to everyday business activities, with most companies and organisations recognising the need to implement robust defences. Against this backdrop, cyber security specialist CYSIAM has made good progress. The business, which provides a 24/7 managed detection and response service, aims to reduce system security breaches and stop ransomware attacks and is a preferred partner to public sector organisations in the UK. The team at CYSIAM are experts in their field, with a background in military intelligence, law enforcement and national security, which has also enabled the business to launch a consultancy arm that is gaining commercial traction. The consultants work with clients to help them understand their security position and build appropriate cyber resilience. CYSIAM has achieved good growth in the year to date and, with a good pipeline of opportunities, the outlook is encouraging.

 

Following changes to the senior leadership team and the appointment of a new CEO, data transfer specialist DiffusionData has delivered strong growth, with ARR nearly doubling since your Company first invested in 2020. The business, which provides a market leading platform to improve the speed, security and efficiency of critical data transfer, is focused on the financial services, gaming and internet of things (IoT) markets, where accurate and timely data transfer is vital. DiffusionData has established a blue chip client base that includes 188 Bet, Baker Technology, Betfair, Caesars, Lloyds Bank and William Hill, with an objective for the year ahead of growing its market position. To support this strategy, a new engineering and testing hub is being established in Newcastle, which will create a number of local jobs and serve as a quality and assurance centre to ensure that DiffusionData can maintain its high standard of service delivery as it scales. In 2022, the business achieved notable industry recognition for its innovative data platform, winning four awards and being shortlisted for a further 12.

 

During the period under review, sustainable packaging manufacturer iPac has continued to deliver a good rate of sales growth and has a strong pipeline of new opportunities. The business, which manufactures and supplies thermoformed sustainable packaging solutions to the food and pharmaceutical sectors, recently opened its sixth production line to accommodate increased demand. In February 2023, it opened a new production and warehousing facility in County Durham, which has created a number of local jobs and has capacity to house up to eight new production lines that will be phased in over time to meet client demand. iPac continues to develop new products and its strategic objective is to move into adjacent markets where there is demand for sustainable packaging solutions. Given its strong and expanding product portfolio, coupled with attractive ESG credentials, the business is well placed to continue to deliver good growth in the year ahead.

 

Crematorium developer and operator Horizon Ceremonies continues to make good operational and strategic progress. Since your Company first invested in 2017, Horizon has established a portfolio of three crematoria, all of which are trading ahead of plan and the business continues to build a strong market position. Whilst the planning process for a new crematorium can be lengthy, there is a good pipeline of opportunities at varying stages of the approval process. The medium term strategic objective remains to build a portfolio of modern, technologically advanced crematoria that offer a professional and compassionate service, whilst also meeting the highest environmental standards, including the objective of achieving net zero status by 2025, and to sell the business to a trade, private equity or infrastructure acquirer when all sites are fully developed.

 

Since your Company first invested in December 2021, Liftango, a provider of environmentally friendly transport planning solutions, has achieved significant commercial traction. The business, which enables clients such as corporates, universities and public transport providers, to plan, launch and scale sustainable transport solutions, including climate-positive carpooling, fixed-route shuttles and on-demand buses, recently signed a five year contract with National Express to digitalise its existing dial-a-ride service, adding to an impressive blue chip list that includes Amazon, IKEA, Tesla, Qantas and Volvo. During the period, Liftango received additional funding from the Maven VCTs as part of a larger funding round supported by existing investors. This further investment will help the business to increase ARR by accelerating its international growth plan and capitalising on emerging opportunities in Europe and North America, whilst also broadening its product offering to existing regions and clients.

 

Digital archiving specialist MirrorWeb continues to deliver impressive revenue growth and has increased ARR by over 80% compared to the prior year. During the period, the business received additional funding from the Maven VCTs to support its expansion into the US, which is regarded as a pivotal market for future growth. The international expansion is being led by the CEO, who relocated to Austin, Texas in early 2023. The strategy for growth in the US will focus on increasing sales by targeting large financial institutions and compliance consultancies, where the need to archive digital communications is either a regulatory or best practice requirement, and where MirrorWeb's comprehensive and secure product offering provides a compelling solution. The business will also continue to build its presence in the UK, where its blue chip customer base includes Aegon, Baillie Gifford, the BBC, HM Treasury, Tesco Bank and The National Archives.

 

During the period under review, Rockar, a developer of a disruptive digital platform for buying new and used cars, has made positive progress and further enhanced its position in the evolving automotive ecommerce market. The business, which provides a white label cloud-based solution to help manufacturers and retailers develop digital alternatives to replace or complement existing showroom models, has achieved good commercial traction and recently added Volvo to its existing client base which includes BMW, Jaguar Land Rover, Porsche and Toyota. The strategy for the year ahead remains focused on building relationships with global automotive manufacturers to enable the business to scale further.

 

Whilst the majority of companies in the unlisted portfolio have continued to make positive progress, there are a small number that have not achieved their commercial targets, largely as a result of conditions within the wider economy. Martel Instruments, a manufacturer and supplier of custom-built compact printers and data loggers, traded very well during the pandemic, buoyed by high demand from customers within the medical devices market. More recently, however, trading has been affected by the well-publicised global shortage of micro processing chips, which are used in printers. The disruption to the supply chain has had an impact on performance during the reporting period and, consequently, the valuation has been reduced. Specialist IT integrator Flow has experienced challenging trading conditions resulting from hardware and component shortages, and a provision against cost has been taken to reflect the lower than expected trading performance.

 

New Investments

 

During the reporting period, two new private companies were added to the portfolio:

 

• iAM Compliant is a software company that has established a strong position in the eLearning market and operates through two core divisions. The first, iAM Compliant, is a cloud-based estates and compliance management platform, covering areas such as estates management, health and safety, status reporting and premises checks. The division has achieved a good rate of recurring revenue and maintains a high client retention rate. The second division, iAM Learning, has developed a digital learning library that contains over 275 continuing professional development (CPD) and Institute of Occupational Safety and Health (IOSH) approved courses covering a wide range of topics such as cyber security, leadership, mental health and safeguarding. The courses are designed to be accessible and engaging, and existing clients include Countrywide, DPD, Dunelm, Lotus Cars and Moonpig. The funding from the Maven VCTs will enable the business to enhance product development, support sales and marketing initiatives, and provide general working capital headroom.

 

• Manufacture 2030 (M2030) has developed a software solution to assist large corporates with complex manufacturing supply chains to work with their suppliers to measure and actively reduce carbon emissions. The platform enables companies to collate environmental impact data and formulate reduction strategies, whilst tracking progress and reporting this to their customers. The business has developed a strong client base, including multi-nationals such as Asda, Bayer, Ford, General Motors, Morrisons and SC Johnson. The funding from the Maven VCTs is being used to expand M2030's market position in key sectors such as automotive, chemical, pharmaceuticals and retail, and to support further product development to enhance the platform functionality.

 

The following investments were completed during the reporting period:

 

Investments

Date

Sector

Investment Cost

£'000

New Unlisted

2 degrees Limited

(trading as Manufacture 2030)

March 2023

Software & technology

598

iAM Compliant Limited

May 2023

Learning & development/ recruitment technology

149

Total new unlisted

747

 

Follow-on unlisted

 

Draper & Dash Limited

(trading as RwHealth)

April 2023

Pharmaceuticals,

biotechnology & healthcare

75

Enpal Limited (trading as Guru Systems)

April 2023

Software & technology

82

Liftango Group Limited

February 2023

Software & technology

200

 

MirrorWeb Limited

February 2023

Software & technology

90

Turnkey Group (UK) Holdings Limited

March 2023

Software & technology

299

Zinc Digital Business Solutions Limited

April 2023

Software & technology

19

Total follow-on unlisted

765

 

 

Total unlisted

1,512

 

Open-ended investment companies1

 

Royal London Short Term Fixed Income Fund (Class Y Income)

February 2023

Money market fund

1,000

Royal London Short Term Money Market Fund (Class Y Income)

March 2023

Money market fund

2,000

Total open-ended investment companies

3,000

 

Money market funds1

 

Aberdeen Standard Liquidity Fund (Lux) - Sterling Fund (Class K3)

April 2023

Money market fund

1,000

Aviva Investors

Sterling Liquidity Fund (Class 3)

April 2023

Money market fund

1,003

BlackRock Institutional Sterling Liquidity Fund (Core)

May 2023

Money market fund

1,000

Fidelity Institutional Liquidity Sterling Fund (Class F)

March 2023

Money market fund

1,010

Goldman Sachs Sterling Government Liquid Reserves Ireland (Institutional)

May 2023

Money market fund

1,000

HSBC Sterling Liquidity Fund (Class A)

May 2023

Money market fund

1,000

Total money market funds

6,013

 

 

Investments

Date

Sector

Investment Cost

£'000

Private equity investment trusts1

abrdn Private Equity Opportunities Trust PLC (formerly Standard Life Private Equity Trust PLC)

March 2023

Investment trust

264

Alliance Trust PLC

May 2023

Investment trust

149

Apax Global Alpha Limited

May 2023

Investment trust

60

HgCapital Trust PLC

March 2023

Investment trust

250

ICG Enterprise Trust PLC

May 2023

Investment trust

73

JPMorgan Global Growth & Income PLC

May 2023

Investment trust

150

NB Private Equity Partners Limited

March 2023

Investment trust

371

Total private equity investment trusts

1,317

 

Real estate investment trust1

Impact Healthcare REIT PLC

May 2023

Investment trust

167

Total real estate investment trust

167

 

Infrastructure investment trusts1

3i Infrastructure PLC

May 2023

Investment trust

270

BBGI Global Infrastructure SA

May 2023

Investment trust

260

International Public Partnerships Limited

May 2023

Investment trust

235

JLEN Environmental Assets Group Limited

May 2023

Investment trust

270

Pantheon Infrastructure PLC

March 2023

Investment trust

251

Total infrastructure investment trusts

1,286

 

 

 

Total investments

 

13,295

 

1 Investments completed as part of the liquidity management strategy, details of which can be found in the investments table on pages 12 and 13 of this Interim Report

 

At the period end, the portfolio stood at 114 unlisted and quoted investments, at a total cost of £48.06 million.

 

 

Realisations

 

The table below gives details of all realisations completed during the reporting period:

 

Realisations

Year

first invested

Complete/

partial

exit

Cost of shares disposed of

£'000

Value at

30 November 2022

£'000

Sales proceeds

£'000

Realised gain/

(loss)

£'000

Gain/(loss) over 30 November 2022 value

£'000

Unlisted

ADC Biotechnology Limited1

2017

Complete

-

-

129

129

129

Ensco 969 Limited (trading as DPP)2

2013

Partial

63

82

63

-

(19)

Maven Co-invest Endeavour Limited Partnership3

2013

Complete

2

499

513

511

14

Optoscribe Limited4

2018

Complete

-

-

40

40

40

R&M Engineering Group Limited

2013

Complete

761

172

120

(641)

(52)

Others

-

-

1

1

1

Total unlisted

 

 

826

753

866

40

113

 

Money Market Funds

Fidelity Institutional Liquidity Sterling Fund (Class F)

2023

Partial

10

-

10

-

10

Total money market funds

 

 

10

-

10

-

10

 

 

 

 

 

 

 

 

Total realisations

 

 

836

753

876

40

123

 

1 Deferred consideration following the sale in March 2021.

2 Proceeds from loan note repayment, which excludes yield received and is disclosed as revenue for financial reporting purposes.

3 Release of monies following the sale of the underlying company in June 2022.

4 Deferred consideration following the sale in January 2022.

 

Principal and Emerging Risks and Uncertainties

 

The principal and emerging risks and uncertainties facing the Company were set out in full in the Strategic Report contained within the 2022 Annual Report, and are the risks associated with investment in small and medium sized unlisted and AIM/AQSE quoted companies which, by their nature, carry a higher level of risk and are subject to lower liquidity than investments in larger quoted companies. The valuation of investee companies may be affected by economic conditions, the credit environment and other risks including legislation, regulation, adherence to VCT qualifying rules and the effectiveness of the internal controls operated by the Company and the Manager. These risks and procedures are reviewed regularly by the Audit & Risk Committee and reported to your Board. The Board has confirmed that all tests, including the criteria for VCT qualifying status, continue to be monitored and met.

 

The invasion of Ukraine by Russia was added to the Risk Register as an emerging risk during a previous period, as the Directors were not only aware of the heightened cyber security risk but were mindful of the impact that any change in the underlying economic conditions could have on the valuation of investment companies. These included fluctuating interest rates, increased fuel and energy costs, and the availability of bank finance, all of which could be impacted during times of geopolitical uncertainty and volatile markets. The Board and the Manager continue to monitor the impact of the conflict, and wider market conditions, on portfolio companies.

 

Share Buy-backs

 

Shareholders will be aware that a primary objective for the Board is to ensure that the Company retains sufficient liquidity for making investments in line with its stated policy, and for the continued payment of dividends. However, the Directors also acknowledge the need to maintain an orderly market in the Company's shares and have, therefore, delegated authority to the Manager for the Company to buy back shares in the market, for cancellation or to be held in treasury, subject always to such transactions being in the best interests of Shareholders.

 

It is intended that the Company should seek to maintain a share price at a discount that is approximately 5% below the latest published NAV per share, subject to market conditions, availability liquidity and the maintenance of the Company's VCT qualifying status.

 

Shareholders should be aware that neither the Company nor the Manager can execute a direct transaction in the Company's shares. Any instruction to buy or sell shares on the secondary market must be directed through a stockbroker, in which case a Shareholder or their broker can contact the Company's Broker, Shore Capital Stockbrokers on 020 7647 8132, to discuss a transaction. It should, however, be noted that such transactions cannot take place whilst the Company is in a closed period, which is the time from the end of a reporting period until the announcement of the relevant results or an unaudited NAV. A closed period may also be introduced if the Directors and Manager are in possession of price sensitive information.

 

During the period under review, 1,317,000 shares were bought back at a total cost of £708,000.

 

VCT Regulatory Update

 

During the period under review, there were no further amendments to the rules governing VCTs. However, Shareholders may be aware that, as approved by the European Commission in 2015, the VCT scheme included a "sunset" clause, which provided that, unless the legislation was renewed by an HM Treasury order, income tax relief would no longer be available on subscriptions for new shares in VCTs made on or after 6 April 2025. There has been a considerable level of activity by industry representatives such as the Venture Capital Trust Association (VCTA), of which the Manager is an active member, and The Association of Investment Companies (AIC), of which the Company is a member, to demonstrate the important role of VCT investment in supporting SMEs across the country and stimulating economic growth and regional employment. The Board and the Manager welcomed the announcement by the UK Government in the Autumn 2022 budget statement, of an intention to extend the income tax relief available on new VCT shares beyond 2025. This commitment was reaffirmed in the Spring 2023 budget, and the Manager will remain involved in discussions regarding the process for implementing this extension.

 

Consistent with industry best practice, the Board and the Manager continue to apply the International Private Equity and Venture Capital Valuation (IPEV) Guidelines (Valuation Guidelines) as the central methodology for all private company valuations. The Valuation Guidelines are the prevailing framework for fair value information in the private equity and venture capital industry and the Directors and the Manager continue to adhere to the Valuation Guidelines when assessing all private company investments.

 

Environmental, Social and Governance (ESG)

 

Whilst your Company's investment policy does not incorporate specific ESG objectives, and investee companies are not required to meet any particular targets, Maven continues to develop its ESG framework and oversight capabilities, recognising the benefits and importance of incorporating these core principles into its investment approach. Early stage ESG due diligence is now a standard part of the pre-investment decision making process and is a core component within the selection criteria, thereby ensuring that all ESG risks and opportunities are fully discussed prior to an investment completing. During the period under review, the Manager has invested additional resource into its ESG capabilities in recognition of the growing importance of this area, and the requirement to record and monitor ESG information across the portfolio.

 

A number of investee companies are already highly focused on the environment or making improvements to society and local communities and have set themselves specific ESG related goals. Where this is not the case, the Manager is able to support and advise on the value of improving these metrics and can help portfolio companies by sharing best practice.

 

The ESG regulatory landscape is evolving, and the Manager provides the Board with regular updates on the latest developments. A relevant regulation is the Task Force on Climate-related Financial Disclosures (TCFD) on which neither the Company nor the Manager are required to report. However, the Board and the Manager acknowledge the aims and importance of the TCFD, and, therefore, reporting in line with TCFD is an objective of the Manager as part of its approach to ESG.

 

The Manager continues to be an active signatory to the UN Principles for Responsible Investment (UNPRI) and is preparing to complete its first UNPRI report to demonstrate its ESG capabilities and commitment to the Principles. Your Company has multiple investments in companies with strong ESG credentials that are achieving growth in expanding markets and the Manager is committed to maintaining a responsible approach to new and existing investments. Additionally, the Manager is a signatory to the Investing in Women Code, which aims to reduce barriers to tools, resources and finance for UK based female entrepreneurs.

 

Constitution of the Board

 

As announced in December 2022, and in the Annual Report, Chairman Atul Devani will stand down from the Board and will not seek re-election at the 2024 AGM. Through its Nomination Committee, the Board will consider its constitution and Shareholders will be notified of the appointment of a new non-executive Director in due course, as well as the Board member that will succeed Atul as Chairman.

 

 

Outlook

 

With good levels of liquidity, your Company's strategy remains focused on further growing and developing the investee company portfolio. The pipeline of potential new investments across Maven's regional network of offices remains strong and it is anticipated that there will be a good rate of new investment through the second half of the year. The Manager will also continue to work closely with existing portfolio companies, particularly those that are growing rapidly and demonstrating the potential to create significant Shareholder value, to ensure that their value is maximised at the point of exit. This dual focus on portfolio expansion and value maximisation is aimed at ensuring that a steady flow of profitable exits occur in support of the objective of providing Shareholders with regular tax free dividends.

 

 

On behalf of the Board

Maven Capital Partners UK LLP

Secretary

 

21 July 2023

 

 

Summary of Investment Changes

 

For the Six Months Ended 31 May 2023

 

 

Valuation

30 November 2022

Net investment/ (disinvestment)

£'000

Appreciation/ (depreciation)

£'000

Valuation

31 May 2023

£'000

%

£'000

%

Unlisted Investments

 

 

 

 

 

 

Equities

Loan stock

29,253

7,861

48.8

13.1

527

173

(778)

(426)

29,002

7,608

47.5

12.5

 

37,114

61.9

700

 (1,204)

36,610

60.0

AIM/AQSE investments1

 

 

 

 

 

 

Equities

2,065

3.4

-

(371)

1,694

2.8

 

Listed investments2

 

 

 

 

 

 

OEICs

-

-

3,000

(15)

2,985

4.9

Money market funds

-

-

6,003

-

6,003

9.8

Investment trusts

1,981

3.3

2,770

30

4,781

7.8

Total investments

41,160

68.6

12,473

(1,560)

52,073

85.3

 

Other net assets

 

18,783

 

31.4

 

-

 

(9,774)

 

9,009

 

14.7

 

Net assets

 

59,943

 

100.0

 

12,473

 

(11,334)

 

61,082

 

100.0

 

1 Shares traded on the Alternative Investment Market (AIM) and the Aquis Stock Exchange (AQSE).

2 These holdings represent the liquidity management portfolio, which has been constructed from a range of carefully selected, permitted non-qualifying holdings in open-ended investment companies (OEICs), investment trusts and money market funds.

 

 

Investment Portfolio Summary

 

As at 31 May 2023

 

Investment

Valuation

 £'000

Cost

£'000

% of total assets

% of equity held

% of equity held by other clients1

Unlisted

 

 

 

 

 

Horizon Ceremonies Limited

(trading as Horizon Cremation)

2,798

1,288

4.7

8.7

44.0

Bright Network (UK) Limited

2,359

1,015

4.0

8.9

31.0

Rockar 2016 Limited (trading as Rockar)

1,427

971

2.4

4.3

15.1

Ensco 969 Limited (trading as DPP)

1,302

1,032

2.2

4.8

29.7

BioAscent Discovery Limited

1,207

199

2.1

5.0

35.0

Nano Interactive Group Limited

1,126

625

1.8

3.7

11.2

NorthRow Limited

(formerly Contego Solutions Limited)

997

997

1.6

8.7

23.5

Relative Insight Limited

953

700

1.6

3.0

28.7

CB Technology Group Limited

914

558

1.5

10.6

64.4

Martel Instruments Holdings Limited

879

671

1.4

12.4

31.8

MirrorWeb Limited

865

490

1.4

3.8

46.1

DiffusionData Limited

(formerly Push Technology Limited)

855

625

1.4

2.9

13.7

Vodat Communications Group (VCG) Holding Limited

852

567

1.4

5.0

26.9

Delio Limited

821

533

1.3

2.5

11.2

Filtered Technologies Limited

816

750

1.3

7.6

17.8

GradTouch Limited

800

400

1.3

4.0

30.7

WaterBear Education Limited

785

370

1.3

7.8

31.4

Hublsoft Group Limited

763

600

1.2

5.5

18.2

Precursive Limited

750

750

1.2

5.4

28.8

HCS Control Systems Group Limited

746

746

1.2

6.1

30.4

Horizon Technologies Consultants Limited

746

448

1.2

3.1

14.1

QikServe Limited

658

658

1.1

3.0

12.8

Bud Systems Limited

647

647

1.1

3.7

13.3

TC Communications Holdings Limited

645

980

1.1

8.3

21.7

Cat Tech International Limited

627

627

1.0

6.0

24.0

2 degrees Limited

(trading as Manufacture 2030)

598

598

1.0

2.1

9.0

Boomerang Commerce Inc

(trading as CommerceIQ)2

580

773

0.9

0.1

0.3

Whiterock Group Limited

557

320

0.9

5.1

24.9

Glacier Energy Services Holdings Limited

544

686

0.9

2.6

25.0

 

 

As at 31 May 2023

 

Investment

Valuation

£'000

Cost

£'000

% of total assets

% of equity held

% of equity held by other clients1

Unlisted

 

 

 

 

 

Liftango Group Limited

498

498

0.8

1.8

12.1

CODILINK UK Limited (trading as Coniq)

450

450

0.7

1.3

3.6

Turnkey Group (UK) Holdings Limited

448

448

0.7

6.9

31.9

Summize Limited

448

448

0.7

2.9

30.2

mypura.com Group Limited (trading as Pura)

431

216

0.7

1.1

21.3

The Algorithm People Limited

420

420

0.7

6.1

10.2

Flow UK Holdings Limited

420

597

0.7

7.0

28.0

Enpal Limited (trading as Guru Systems)

381

381

0.6

3.2

18.4

Novatus Global Limited

(formerly Novatus Advisory Limited)

348

348

0.6

2.3

11.0

Biorelate Limited

348

348

0.6

2.0

23.7

Plyable Limited

348

348

0.6

3.3

14.1

HiveHR Limited

346

346

0.6

4.4

40.2

CYSIAM Limited

336

199

0.6

3.5

16.5

Project Falcon Topco Limited (trading as Quorum Cyber)3

335

335

0.5

0.8

2.1

ORCHA Health Limited

332

332

0.5

1.4

4.2

Kanabo GP Limited4

331

1,611

0.5

13.5

53.6

Growth Capital Ventures Limited

331

319

0.5

5.8

41.6

Snappy Shopper Limited

298

298

0.5

0.4

1.3

Draper & Dash Limited (trading as RwHealth)

274

274

0.4

1.0

12.6

ebb3 Limited

265

326

0.4

9.3

69.6

Shortbite Limited (trading as Fixtuur)

254

423

0.4

5.6

51.7

XR Games Limited

242

149

0.4

0.8

19.4

Zinc Digital Business Solutions Limited

218

218

0.4

3.3

20.6

Rico Developments Limited

(trading as Adimo)

200

200

0.3

1.5

8.2

FodaBox Limited

199

199

0.3

0.7

4.4

iAM Compliant Limited

149

149

0.2

1.9

36.9

ISN Solutions Group Limited

127

321

0.2

4.5

50.5

Reed Thermoformed Packaging Limited (trading as iPac)

106

100

0.2

0.5

11.8

RevLifter Limited

100

100

0.2

1.0

25.6

Other unlisted investments

10

1,206

-

Total unlisted

36,610

31,231

60.0

 

 

 

 

As at 31 May 2023

 

Investment

Valuation £'000

Cost

£'000

% of total assets

% of equity

held

% of equity held by other clients1

AIM/AQSE quoted

GENinCode PLC

440

598

0.7

3.5

7.5

MaxCyte Inc

262

137

0.5

0.1

0.1

Faron Pharmaceuticals Oy

194

250

0.3

0.1

-

Diaceutics PLC

169

161

0.3

0.3

0.3

C4X Discovery Holdings PLC

125

119

0.2

0.3

0.6

Destiny Pharma PLC

68

150

0.1

0.3

1.2

Spectral MD Holdings PLC

67

99

0.1

0.1

0.1

Feedback PLC

67

121

0.1

0.4

1.2

AFC Energy PLC

54

57

0.1

-

-

Polarean Imaging PLC

50

129

0.1

0.1

0.5

Eden Research PLC

48

83

0.1

0.4

1.0

Crossword Cybersecurity PLC

37

122

0.1

0.4

1.7

RUA Life Sciences PLC

32

100

0.1

0.4

1.3

ReNeuron Group PLC

22

278

-

0.7

1.4

Pelatro PLC

19

146

-

0.6

1.8

Vianet Group PLC

18

31

-

0.1

1.4

Oncimmune Holdings PLC

10

100

-

0.1

0.4

Other quoted investments

12

885

-

Total AIM/AQSE quoted

1,694

3,566

2.8

 

 

 

Private equity investment trusts5

 

 

 

 

 

HgCapital Trust PLC

648

420

1.1

-

0.1

abrdn Private Equity Opportunities Trust PLC (formerly Standard Life Private Equity Trust PLC)

411

374

0.7

-

0.1

ICG Enterprise Trust PLC

382

300

0.6

0.1

0.1

NB Private Equity Partners Limited

346

371

0.6

-

-

CT Private Equity Trust PLC

(formerly BMO Private Equity Trust PLC)

337

253

0.6

0.1

0.3

Princess Private Equity Holding Limited

266

270

0.4

0.1

0.1

HarbourVest Global Private Equity Limited

254

167

0.4

-

0.1

Apax Global Alpha Limited

240

219

0.4

-

0.1

Pantheon International PLC

179

138

0.3

-

0.1

JPMorgan Global Growth & Income PLC

149

150

0.2

-

-

Alliance Trust PLC

148

149

0.2

-

-

Total private equity investment trusts

3,360

2,811

5.5

 

 

 

 

As at 31 May 2023

 

Investment

Valuation £'000

Cost

£'000

% of total assets

% of equity

held

% of equity held by other clients1

Real estate investment trust5

Impact Healthcare REIT PLC

172

167

0.3

-

0.1

Total real estate investment trust

172

167

0.3

 

 

 

Infrastructure investment trusts5

JLEN Environmental Assets Group Limited

262

270

0.4

-

0.1

3i Infrastructure PLC

261

270

0.4

-

-

BBGI Global Infrastructure SA

253

260

0.4

-

0.1

Pantheon Infrastructure PLC

246

251

0.4

0.1

0.2

International Public Partnerships Limited

227

235

0.4

-

-

Total infrastructure investment trusts

1,249

1,286

2.0

 

 

 

Open-ended investment companies5

 

 

 

 

 

Royal London Short Term Money Market Fund (Class Y Income)

1,983

2,000

3.3

-

-

Royal London Short Term Fixed Income Fund (Class Y Income)

1,002

1,000

1.6

-

0.1

Total open-ended investment companies

2,985

3,000

4.9

 

 

 

Money market funds5

Aviva Investors Sterling Liquidity Fund (Class 3)

1,003

1,002

1.8

-

-

Aberdeen Standard Liquidity Fund (Lux) - Sterling Fund (Class K3)

1,000

1,000

1.6

-

-

BlackRock Institutional Sterling Liquidity Fund (Core)

1,000

1,000

1.6

-

0.1

Fidelity Institutional Liquidity Sterling Fund (Class F)

1,000

1,000

1.6

0.1

0.1

Goldman Sachs Sterling Government Liquid Reserves Ireland (Institutional)

1,000

1,000

1.6

0.3

0.3

HSBC Sterling Liquidity Fund (Class A)

1,000

1,000

1.6

-

-

Total money market funds

6,003

6,002

9.8

 

 

 

 

 

 

 

 

Total investments

52,073

48,063

85.3

 

 

 

1 Other clients of Maven Capital Partners UK LLP.

2 The holding reflects the retained minority interest following the sale of e.fundamentals (Group) Limited to CommerceIQ in July 2022.

3 Retained minority interest following the sale of Quorum Cyber Security Limited in December 2021.

4 The holding in this investment resulted from the sale of The GP Service (UK) Limited to Kanabo GP Limited in a share for share exchange, which completed in February 2022.

5 Liquidity management portfolio.

 

Shaded line indicates that the investment was completed pre November 2015.

 

 

Income Statement

 

For the six months ended 31 May 2023

 

 

Six months ended

31 May 2023

(unaudited)

Six months ended

31 May 2022

(unaudited)

Year ended

30 November 2022

(audited)

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

(Losses)/gains on investments

-

(1,560)

(1,560)

-

(1,378)

(1,378)

-

626

626

Income from investments

323

-

323

435

-

435

730

-

730

Other income

147

-

147

3

-

3

55

-

55

Investment management fees

(154)

(616)

(770)

(132)

(528)

(660)

(277)

(1,111)

(1,388)

Other expenses

(241)

-

(241)

(179)

-

(179)

(479)

-

(479)

Net return on ordinary activities before taxation

75

(2,176)

(2,101)

127

(1,906)

(1,779)

29

(485)

(456)

 

Tax on ordinary activities

 

-

 

-

 

-

 

(8)

 

8

 

-

 

-

 

-

 

-

Return attributable to Equity Shareholders

75

(2,176)

(2,101)

119

(1,898)

(1,779)

29

(485)

(456)

 

Earnings per share (pence)

 

0.07

 

(1.99)

 

(1.92)

 

0.13

 

(2.10)

 

(1.97)

 

0.03

 

(0.50)

 

(0.47)

 

All gains and losses are recognised in the Income Statement.

 

The total column of this statement is the Profit & Loss Account of the Company. The revenue and capital columns are supplementary to this and are prepared under guidance published by the AIC. All items in the above statement are derived from continuing operations. The Company has only one class of business and one reportable segment, the results of which are set out in the Income Statement and Balance Sheet. The Company derives its income from investments made in shares, securities and bank deposits.

 

There are no potentially dilutive capital instruments in issue and, therefore, no diluted earnings per share figures are relevant. The basic and diluted earnings per share are, therefore, identical.

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Statement of Changes in Equity

 

Six Months Ended 31 May 2023

 

Six months ended 31 May 2023 (unaudited)

 

Non-distributable reserves

Distributable reserves

Total

£'000

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve unrealised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

At 30 November 2022

10,457

19,920

346

7,422

1,050

19,974

774

59,943

Net return

-

-

-

(1,545)

(15)

(616)

75

(2,101)

Dividends paid

-

-

-

-

-

(2,112)

-

(2,112)

Repurchase and cancellation

of shares

(132)

-

132

-

-

(708)

-

(708)

Net proceeds of share issue

1,024

4,801

-

-

-

-

-

5,825

Net proceeds of DIS issue*

42

193

-

-

-

-

-

235

At 31 May 2023

11,391

24,914

478

5,877

1,035

16,538

849

61,082

 

Six months ended 31 May 2022 (unaudited)

 

Non-distributable reserves

Distributable reserves

Total

£'000

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve unrealised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

At 30 November 2021

7,866

6,436

287

9,669

(1,823)

26,020

745

49,200

Net return

-

-

-

(5,085)

3,707

(520)

119

(1,779)

Dividends paid

-

-

-

-

-

(3,299)

-

(3,299)

Repurchase and cancellation of shares

(24)

-

24

-

-

(138)

-

(138)

Net proceeds of share issue

2,303

11,841

-

-

-

-

-

14,144

Net proceeds of DIS issue*

28

118

-

-

-

-

-

146

At 31 May 2022

10,173

18,395

311

4,584

1,884

22,063

864

58,274

 

Year ended 30 November 2022 (audited)

 

Non-distributable reserves

Distributable reserves

Total

£'000

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve unrealised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

At 30 November 2021

7,866

6,436

287

9,669

(1,823)

26,020

745

49,200

Net return

-

-

-

(2,247)

2,873

(1,111)

29

(456)

Dividends paid

-

-

-

-

-

(4,607)

-

(4,607)

Repurchase and cancellation of shares

(59)

-

59

-

-

(328)

-

(328)

Net proceeds of share issue

2,562

13,074

-

-

-

-

-

15,636

Net proceeds of DIS issue*

88

410

-

-

-

-

-

498

At 30 November 2022

10,457

19,920

346

7,422

1,050

19,974

774

59,943

 

The capital reserve unrealised is generally non-distributable other than the part of the reserve relating to gains/(losses) attributable to readily realisable quoted investments which are distributable.

 

Where all, or an element of the proceeds of sales have not been received in cash or cash equivalent, and are not readily convertible to cash, they do not qualify as realised gains for the purposes of distributable reserves calculations and, therefore, do not form part of distributable reserves.

 

*DIS represents the Dividend Investment Scheme, as detailed in the Investment Manager's Review in the Interim Report.

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Balance Sheet

 

As at 31 May 2023

 

31 May 2023

(unaudited)

£'000

31 May 2022

(unaudited)

£'000

30 November 2022

(audited)

£'000

Fixed assets

Investments at fair value through profit or loss

 

Current assets

Debtors

Cash

 

52,073

 

 

665

8,528

 

38,297

 

 

512

19,528

 

41,160

 

 

703

18,261

 

9,193

20,040

18,964

Creditors

Amounts falling due within one year

(184)

(63)

(181)

Net current assets

9,009

19,977

18,783

Net assets

61,082

58,274

59,943

 

Capital and reserves

Called up share capital

Share premium account

Capital redemption reserve

Capital reserve - unrealised

Capital reserve - realised

Special distributable reserve

Revenue reserve

 

 

11,391

24,914

478

5,877

1,035

16,538

849

 

 

10,173

18,395

311

4,584

1,884

22,063

864

 

 

10,457

19,920

346

7,422

1,050

19,974

774

Net assets attributable to Ordinary Shareholders

61,082

58,274

59,943

Net asset value per Ordinary Share (pence)

53.62

57.28

57.32

 

The Financial Statements of Maven Income and Growth VCT 3 PLC, registered number 04283350, were approved by the Board and were signed on its behalf by:

 

 

 

Atul Devani

Director

 

21 July 2023

 

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Cash Flow Statement

 

For the six months ended 31 May 2023

 

Six months ended 31 May 2023 (unaudited)

£'000

Six months ended

31 May 2022

 (unaudited)

£'000

Year ended

30 November 2022 (audited)

£'000

Net cash flows from operating activities

(556)

(735)

(1,329)

 

Cash flows from investing activities

Purchase of investments

Sale of investments

 

 

(13,295)

896

 

 

(1,527)

5,289

 

 

(5,626)

8,369

Net cash flows from investing activities

(12,399)

3,762

2,743

 

Cash flows from financing activities

Equity dividends paid

Issue of Ordinary Shares

Repurchase of Ordinary Shares

 

 

(2,112)

6,042

(708)

 

 

(3,299)

14,290

(138)

 

 

(4,607)

16,134

(328)

Net cash flows from financing activities

3,222

10,853

11,199

 

Net (decrease)/increase in cash

 

(9,733)

 

13,880

 

12,613

 

Cash as at beginning of period

 

18,261

 

5,648

 

5,648

Cash at end of period

8,528

19,528

18,261

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Notes to the Financial Statements

 

1. Accounting Policies

 

The financial information for the six months ended 31 May 2023 and the six months ended 31 May 2022 comprises non-statutory accounts within the meaning of S435 of the Companies Act 2006. The financial information contained in this report has been prepared on the basis of the accounting policies set out in the Annual Report and Financial Statements for the year ended 30 November 2022, which have been filed at Companies House and contained an Auditor's Report that was not qualified and did not contain a statement under S498(2) or S498(3) of the Companies Act 2006.

 

2. Reserves

 

Share premium account

 

The share premium account represents the premium above nominal value received by the Company on issuing shares net of issue costs. This reserve is non-distributable.

 

Capital redemption reserve

 

The nominal value of shares repurchased and cancelled is represented in the capital redemption reserve. This reserve is non-distributable.

 

Capital reserve - unrealised

 

Increases and decreases in the fair value of investments are recognised in the Income Statement and are then transferred to the capital reserve unrealised account. This reserve is generally non-distributable other than the part of the reserve relating to gains/(losses) attributable to readily realisable quoted investments which are distributable.

 

Capital reserve - realised

 

Gains or losses on investments realised in the year that have been recognised in the Income Statement are transferred to the capital reserve realised account on disposal. Furthermore, any prior unrealised gains or losses on such investments are transferred from the capital reserve unrealised account to the capital reserve realised account on disposal. This reserve is distributable.

 

Special distributable reserve

 

The total cost to the Company of the repurchase and cancellation of shares is represented in the special distributable reserve account. The special distributable reserve also represents capital dividends, capital investment management fees and the tax effect of capital items. This reserve is distributable.

 

Revenue reserve

 

The revenue reserve represents accumulated profits retained by the Company that have not been distributed to Shareholders as a dividend. This reserve is distributable.

 

3. Return per Ordinary Share

 

Six months ended 31 May 2023

The returns per share have been based on the following figures:

Weighted average number of Ordinary Shares

109,430,676

 

Revenue return

 

£75,000

Capital return

(£2,176,000)

Total return

(£2,101,000)

 

Directors' Responsibility Statement

 

Each Director believes that, to the best of their knowledge:

 

• the Financial Statements for the six months ended 31 May 2023 have been prepared in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland;

 

• the Interim Management Report includes a fair review of the information required by DTR 4.2.7R in relation to the indication of important events during the first six months, and of the principal and emerging risks and uncertainties facing the Company during the second six months, of the year ending 30 November 2023; and

 

• the Interim Management Report includes adequate disclosure of the information required by DTR 4.2.8R in relation to material related party transactions and any changes therein.

 

Other information

 

The NAV per Ordinary Share has been calculated using the number of Ordinary Shares in issue at 31 May 2023, which was 113,917,040. A summary of investment changes for the six months under review and an investment portfolio summary as at 31 May 2023 are included above. A full copy of the Interim Report and Financial Statements will be printed and issued to Shareholders in due course. Copies of this announcement will be available to the public at the office of Maven Capital Partners UK LLP, Kintyre House, 205 West George Street, Glasgow, G2 2LW; at the Registered office of the Company at 6th Floor, Saddlers House, 44 Gutter Lane, London EC2V 6BR; and on the Company's website at: mavencp.com/migvct3.

 

Neither the content of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

 

On behalf of the Board

Maven Capital Partners UK LLP

Secretary

 

21 July 2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FFLFLXDLEBBB
Date   Source Headline
26th Apr 20242:40 pmRNSNet Asset Value - Dividend Investment Scheme
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:37 pmRNSIssue of Equity
28th Mar 202410:16 amRNSStatement re Offer for Subscription
27th Mar 202410:36 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:46 pmRNSUnaudited Net Asset Value
15th Mar 20245:18 pmRNSAnnual Financial Report
21st Feb 20244:24 pmRNSTransaction in Own Shares
8th Feb 202410:30 amRNSDirector/PDMR Shareholding
8th Feb 202410:28 amRNSDirector/PDMR Shareholding
8th Feb 202410:15 amRNSIssue of Equity
6th Feb 202411:07 amRNSDividend Declaration
19th Dec 20233:25 pmRNSIssue of Equity
18th Dec 20235:17 pmRNSUnaudited Net Asset Value
5th Dec 202311:42 amRNSDirectorate Change
9th Nov 20233:47 pmRNSResult of General Meeting
8th Nov 20234:01 pmRNSTransaction in Own Shares
7th Nov 20234:47 pmRNSTransaction in Own Shares
19th Oct 20234:15 pmRNSNet Asset Value
13th Oct 20234:56 pmRNSPublication of a Prospectus
25th Aug 20239:38 amRNSIssue of Equity
21st Aug 20233:28 pmRNSStatement re Dividend Investment Scheme
21st Jul 202312:52 pmRNSHalf-year Report
13th Jul 20234:04 pmRNSTransaction in Own Shares
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
30th Jun 20234:22 pmRNSNet Asset Value and Interim Dividend
2nd Jun 20239:41 amRNSIssue of Equity
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
26th Apr 202310:15 amRNSIssue of Equity - Dividend Investment Scheme
24th Apr 202312:51 pmRNSResult of AGM
19th Apr 20234:49 pmRNSTransaction in Own Shares
19th Apr 20231:05 pmRNSNet Asset Value - Dividend Investment Scheme
5th Apr 202312:29 pmRNSIssue of Equity
4th Apr 202311:43 amRNSNet Asset Value(s)
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
14th Mar 20234:31 pmRNSAnnual Financial Report
3rd Mar 20239:53 amRNSIssue of Equity
21st Feb 20234:41 pmRNSTransaction in Own Shares
16th Feb 20237:00 amRNSStatement re Offer for Subscription
8th Feb 202311:06 amRNSDirector/PDMR Shareholding - Replacement
8th Feb 202310:19 amRNSDirector/PDMR Shareholding
8th Feb 202310:19 amRNSDirector/PDMR Shareholding
8th Feb 202310:08 amRNSDirector/PDMR Shareholding
8th Feb 20239:43 amRNSIssue of Equity
1st Feb 20233:23 pmRNSUnaudited NAV and Proposed Final Dividend
12th Dec 20223:41 pmRNSDirectorate Change
12th Dec 20223:34 pmRNSStatement re Director's Other Quoted Directorships
9th Nov 20223:00 pmRNSResult of General Meeting
4th Nov 20222:35 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.